{"id":449,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-triple-agonist-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/retatrutide-triple-agonist-phase-2-evidence\/","title":{"rendered":"Agonismo triplo Retatrutide: o que o ensaio da fase 2 encontrou - e n\u00e3o provou"},"content":{"rendered":"

Retatrutide foi projetado para ativar os receptores GIP, GLP-1 e glucagon em uma mol\u00e9cula. Seu ensaio de obesidade da fase 2023 2 gerou interesse substancial, mas a interpreta\u00e7\u00e3o correta depende da fase do ensaio, da popula\u00e7\u00e3o, dos desfechos, dos resultados de eventos adversos e do que permaneceu desconhecido.<\/p>

Principais conclus\u00f5es<\/h2>
  • Retatrutide \u00e9 uma \u00fanica mol\u00e9cula experimental com atividade em tr\u00eas receptores hormonais.<\/li>
  • Os resultados frequentemente citados v\u00eam de um teste 2 da fase 338 do participante, n\u00e3o de uma decis\u00e3o de aprova\u00e7\u00e3o.<\/li>
  • A conclus\u00e3o do estudo da fase 3 n\u00e3o significa, por si s\u00f3, que os resultados sejam publicados ou que um produto seja aprovado.<\/li><\/ul><\/div><\/div>
    \"Pesquisador
    Ilustra\u00e7\u00e3o editorial original de tr\u00eas vias de sinaliza\u00e7\u00e3o de receptor em um laborat\u00f3rio de pesquisa; n\u00e3o \u00e9 uma representa\u00e7\u00e3o da administra\u00e7\u00e3o cl\u00ednica.<\/figcaption><\/figure>

    O conceito de tr\u00eas receptores<\/h2>

    Retatrutide, tamb\u00e9m identificado nos registros de desenvolvimento como LY3437943, \u00e9 um agonista dos receptores GIP, GLP-1 e glucagon. Cham\u00e1-lo de agonista triplo descreve a farmacologia do receptor; n\u00e3o prev\u00ea por si s\u00f3 a magnitude, durabilidade ou seguran\u00e7a de um resultado numa determinada popula\u00e7\u00e3o.<\/p>

    O equil\u00edbrio da atividade entre os tr\u00eas receptores, o perfil de exposi\u00e7\u00e3o da mol\u00e9cula e a formula\u00e7\u00e3o estudada contribuem para os efeitos observados.<\/p>

    O que o estudo de fase 2 mediu<\/h2>

    O ensaio randomizado, duplo-cego e controlado por placebo inscreveu adultos 338 com obesidade ou sobrepeso e uma condi\u00e7\u00e3o relacionada ao peso. O endpoint prim\u00e1rio foi a altera\u00e7\u00e3o percentual no peso corporal nas semanas 24; A mudan\u00e7a na semana 48 e os limites categ\u00f3ricos de redu\u00e7\u00e3o de peso foram desfechos secund\u00e1rios. Os eventos gastrointestinais foram os eventos adversos mais comuns, e foram observados aumentos da frequ\u00eancia card\u00edaca dependentes da dose, antes de diminuir mais tarde no estudo.<\/p>

    O estudo estabeleceu um sinal dose-resposta e apoiou o desenvolvimento da fase 3. N\u00e3o estabeleceu risco-benef\u00edcio a longo prazo em popula\u00e7\u00f5es mais amplas, superioridade direta sobre todas as alternativas ou equival\u00eancia entre material de ensaio e um produto de cat\u00e1logo.<\/p>

    Projeto<\/strong>Ensaio de fase 2 randomizado, duplo-cego e controlado por placebo<\/span><\/div>
    Participantes<\/strong>338 adultos<\/span><\/div>
    Dura\u00e7\u00e3o<\/strong>Semanas 48<\/span><\/div>
    Limite chave<\/strong>Evid\u00eancia investigacional, n\u00e3o uma aprova\u00e7\u00e3o FDA<\/span><\/div><\/div><\/div>

    O que mudou em 2026<\/h2>

    ClinicalTrials.gov lista TRIUMPH-1 como um estudo de fase completa 3, com conclus\u00e3o do estudo em abril 2026 e nenhum resultado publicado no registro revisado para este artigo. \u201cConclu\u00eddo\u201d descreve o status do estudo; n\u00e3o substitui resultados, revis\u00e3o por pares ou avalia\u00e7\u00e3o regulat\u00f3ria.<\/p>

    As informa\u00e7\u00f5es p\u00fablicas atuais do FDA afirmam que a retatrutida n\u00e3o \u00e9 um componente de um medicamento aprovado pelo FDA. Um artigo 2026 preciso deve, portanto, descrev\u00ea-lo como investigacional, a menos e at\u00e9 que um registro de aprova\u00e7\u00e3o oficial diga o contr\u00e1rio.<\/p>

    Linha superior da Fase 3 relatada pelo patrocinador 2026<\/h2>

    Lilly relatou resultados principais para TRIUMPH-1 em maio 21, 2026: nas semanas 80, o patrocinador relatou altera\u00e7\u00e3o m\u00e9dia de peso de \u221228.3% para o grupo 12 mg. Em julho 23, 2026, Lilly relatou mudan\u00e7as m\u00e9dias de at\u00e9 \u221220.8% em TRIUMPH-2 e \u221222.6% em TRIUMPH-3. Estas s\u00e3o divulga\u00e7\u00f5es do patrocinador principal, n\u00e3o m\u00f3dulos de resultados do ClinicalTrials.gov ou relat\u00f3rios completos revisados \u200b\u200bpor pares; m\u00e9todos detalhados, decis\u00f5es de an\u00e1lise e tabelas completas de eventos adversos ainda exigem registros completos. ClinicalTrials.gov continuou a mostrar \u201cNenhum resultado publicado\u201d para TRIUMPH-1 nesta revis\u00e3o.<\/p>","protected":false},"excerpt":{"rendered":"

    Uma leitura atenta da farmacologia do receptor GIP, GLP-1 e do glucagon da retatrutida e do estudo de obesidade 2 de fase semanal 48, incluindo limita\u00e7\u00f5es e status investigacional atual.<\/p>","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Clinical trial evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Primary randomized phase 2 record; PMID 37366315.\"},{\"title\":\"TRIUMPH-1 phase 3 study record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"ClinicalTrials.gov record updated June 2026; results not posted in the reviewed record.\"},{\"title\":\"FDA information on unapproved GLP-1 products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nRetatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD<\/title>\n<meta name=\"description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\" \/>\n<meta property=\"og:description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Agonismo triplo Retatrutide: o que o ensaio da fase 2 encontrou - e n\u00e3o provou - NHD","description":"Uma leitura atenta da farmacologia do receptor GIP, GLP-1 e do glucagon da retatrutida e do estudo de obesidade 2 de fase semanal 48, incluindo limita\u00e7\u00f5es e status investigacional atual.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/retatrutide-triple-agonist-phase-2-evidence\/","og_locale":"pt_BR","og_type":"article","og_title":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","og_description":"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.","og_url":"https:\/\/nhdbio.com\/pt-br\/retatrutide-triple-agonist-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","name":"Agonismo triplo Retatrutide: o que o ensaio da fase 2 encontrou - e n\u00e3o provou - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Uma leitura atenta da farmacologia do receptor GIP, GLP-1 e do glucagon da retatrutida e do estudo de obesidade 2 de fase semanal 48, incluindo limita\u00e7\u00f5es e status investigacional atual.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=449"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/449\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/449\/revisions\/528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}